Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | The promise of brentuximab vedotin for the treatment of pediatric HL

Kara Kelly • 5 Jun 2022
ASCO 2022
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin

Kara Kelly, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares some results from a Phase III trial investigating the efficacy of brentuximab vedotin plus chemotherapy versus standard of care in children and adolescents with Hodgkin lymphoma. Dr Kelly highlights the improved event-free survival (EFS) observed, and further comments on the excitement surrounding these results and the promise of brentuximab vedotin for the treatment of HL. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Kara Kelly

1:56
Toxicities associated with brentuximab vedotin in pediatric and adolescent Hodgkin lymphoma
Kara Kelly • 5 Jun 2022
1:14
Survival gap between adult and pediatric cases of Hodgkin lymphoma
Kara Kelly • 5 Jun 2022

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals